Date:2021-8-3
Your Name: Linghui Kong
Manuscript Title:_ A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR
downstream signaling pathways in colorectal cancer_
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
	1	Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Commant for attackling	W W	
7	Support for attending meetings and/or travel	_ X None	
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	_ X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	_ X None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	V None	
13	financial interests	X None	
	illialiciai liiterests		
Dla	ase summarize the above c	anflict of interest in the fo	llowing hove
FIE	ase summarize the above c	office of fifterest in the it	mowing box.

__ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:2021-8-3
Your Name: Qun Zhang
Manuscript Title: A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR
downstream signaling pathways in colorectal cancer_
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	X None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ X None	
4	Consulting fees	_ X None	

_		Y	
5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending	X None	
•	meetings and/or travel	_ XNone	
	meetings and, or traver		
8	Patents planned, issued or	X None	
	pending		
	-		
9	Participation on a Data	X None	
,	Safety Monitoring Board or	_ XNone	
	Advisory Board		
	•		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests	XNone	
	maricial interests		
Ple	ease summarize the above co	onflict of interest in the f	ollowing box:

__ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:2021-8-3
Your Name: Jialei Mao
Manuscript Title: A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR
downstream signaling pathways in colorectal cancer_
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ X None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ X None	
4	Consulting fees	_ X None	

Е	Dayment or henerarie for	V	Nama				
5	Payment or honoraria for lectures, presentations,	X _	_None				
	speakers bureaus,						
	manuscript writing or						
	educational events						
6	Payment for expert	Х	None				
	testimony						
7	Support for attending meetings and/or travel	_ X	_None				
	meetings and/or traver						
8	Patents planned, issued or	Х	None				
	pending	^_	_140116				
9	Participation on a Data	_ X	_None				
	Safety Monitoring Board or						
	Advisory Board						
10	Leadership or fiduciary role	X_	_None				
	in other board, society, committee or advocacy						
	group, paid or unpaid						
11	Stock or stock options	Х	None				
	•						
12	Receipt of equipment,	Х	None				
	materials, drugs, medical						
	writing, gifts or other						
	services						
13	Other financial or non-	X _	_None				
	financial interests						
Ple	ease summarize the above c	onflict (of interest in	the followi	ng box:		

__ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:2021-8-3
Your Name: Lei Cheng
Manuscript Title: A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR
downstream signaling pathways in colorectal cancer_
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	V N	
6	Payment for expert testimony	X None	
	testimony		
7	Support for attending	V Name	
′	meetings and/or travel	_ X None	
	meetings and/or traver		
0	Datanta planned issued as	V Name	
8	Patents planned, issued or pending	X None	
	pending		
9	Participation on a Data	X None	
9	Safety Monitoring Board or	_ XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	_ X None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	Y N	
13	financial interests	X None	
	illialiciai liiterests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:

__ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:2021-8-3
Your Name: Xiao Shi
Manuscript Title: A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR
downstream signaling pathways in colorectal cancer_
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

_					
5	Payment or honoraria for	x_	None		
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or educational events				
6	Payment for expert	Х	None		
٠	testimony	^_	None		
	testimony				
7	Support for attending	Х	None		
,	meetings and/or travel	-^-	None		
	meetings and, or traver				
0	Determination of investor				
8	Patents planned, issued or pending	X	None		
	penullig				
0	Participation on a Data	V	Nama		
9	Participation on a Data Safety Monitoring Board or	_ X	None		
	Advisory Board				
10	Leadership or fiduciary role	V	N		
10	in other board, society,	X	None		
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	х	None		
	φ.	~_			
12	Receipt of equipment,	Х	None		
12	Receipt of equipment, materials, drugs, medical	_x	None		
12		_X	None		
12	materials, drugs, medical writing, gifts or other services	_x	None		
12	materials, drugs, medical writing, gifts or other services Other financial or non-		None None		
	materials, drugs, medical writing, gifts or other services				
	materials, drugs, medical writing, gifts or other services Other financial or non-				
	materials, drugs, medical writing, gifts or other services Other financial or non-				
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	x	None		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	x	None	llowing box:	
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	x	None	llowing box:	
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	x	None	llowing box:	
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	x	None	llowing box:	
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	x	None	llowing box:	
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	x	None	llowing box:	
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	x	None	llowing box:	
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	x	None	llowing box:	
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	x	None	llowing box:	
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	x	None	llowing box:	
Ple	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	X	None f interest in the fo		

__ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:2021-8-3
Your Name: Lixia Yu
Manuscript Title: A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR
downstream signaling pathways in colorectal cancer_
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ X None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ X None	
4	Consulting fees	_ X None	

5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	V N	
6	Payment for expert testimony	X None	
	testimony		
7	Support for attending	V Name	
′	meetings and/or travel	_ X None	
	meetings and/or traver		
0	Datanta planned issued as	V Name	
8	Patents planned, issued or pending	X None	
	pending		
9	Participation on a Data	X None	
9	Safety Monitoring Board or	_ XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	_ X None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	Y N	
13	financial interests	X None	
	illialiciai liiterests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:

__ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:2021-8-3				
Your Name: Jing Hu				
Manuscript Title: A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR				
downstream signaling pathways in colorectal cancer_				
Manuscript number (if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	V N	
6	Payment for expert testimony	X None	
	testimony		
7	Support for attending	V Name	
′	meetings and/or travel	_ X None	
	meetings and/or traver		
0	Datanta planned issued as	V Name	
8	Patents planned, issued or pending	X None	
	pending		
9	Participation on a Data	X None	
9	Safety Monitoring Board or	_ XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	_ X None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	Y N	
13	financial interests	X None	
	illialiciai liiterests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:

__ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:2021-8-3
Your Name: Mi Yang
Manuscript Title: A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR
downstream signaling pathways in colorectal cancer_
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	V N	
6	Payment for expert testimony	X None	
	testimony		
7	Support for attending	V Name	
′	meetings and/or travel	_ X None	
	meetings and/or traver		
0	Datanta planned issued as	V Name	
8	Patents planned, issued or pending	X None	
	pending		
9	Participation on a Data	X None	
9	Safety Monitoring Board or	_ XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	_ X None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	Y N	
13	financial interests	X None	
	illialiciai liiterests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:

__ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:2021-8-3			
Your Name: Li Li			
Manuscript Title: A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR			
downstream signaling pathways in colorectal cancer_			
Manuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	X None	
	testimony		
7	Cumpart for attending	Y N	
7	Support for attending meetings and/or travel	_ X None	
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	_ X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
	Stock of Stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:

__ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:2021-8-3			
Your Name: Baorui Liu			
Manuscript Title: A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR			
downstream signaling pathways in colorectal cancer_			
Manuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	V Name	
U	testimony	X None	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	_ XNone	
	5 ,		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	_ X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
	Stock of Stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fo	llowing box:
_			

__ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:2021-8-3			
Your Name: Xiaoping Qian			
Manuscript Title: A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR			
downstream signaling pathways in colorectal cancer_			
Manuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_ XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	X None	
	testimony		
7	Cumpart for attending	Y N	
7	Support for attending meetings and/or travel	_ X None	
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	_ X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
	Stock of Stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:

__ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.